Our mission is not to just bring a new immunotherapy drug to the market, but to create a new multi-billion dollar biopharmaceutical industry that will eventually replace marginally effective and highly toxic cancer treatments with highly effective and minimally toxic immunotherapy products. Immunotherapy is the only treatment modality that has the technological capability to cure cancer. The immune system can locate and eliminate the last tumor cell, something that is not feasible for a surgeon’s scalpel, radiation or chemotherapy. Without this ability, the tumors recur and spread. There is no cure for metastatic cancer. In addition, the immune system has the special feature of memory. Once the immune system sterilizes the body of all disease, it remembers the cancer so that if the disease should return in the future, the immune system is capable of rising up and protecting against disease without any further treatment. Our goal is to fast track to FDA approval and revenues and then reinvest profits into research and development efforts that will eventually lead us to optimize our immunotherapy drugs in order to develop a cure for cancer in our lifetime.